The FDA accepted Besremi's application for essential thrombocythemia, supported by SURPASS-ET and EXCEED-ET trial results, with a review target date of August 30, 2026. Essential thrombocythemia is a ...
The sBLA is supported by data from the phase 3 SURPASS-ET trial, as well as confirmatory data from the phase 2b EXCEED-ET trial.
Educated Patient® MPN Summit Defining Essential Thrombocythemia Risk Presentation: November 19, 2022
Understanding the different types of risks faced by people with essential thrombocythemia, a type of cancer associated with uncontrolled growth of blood platelets, is crucial to helping patients live ...
Taiwan-based PharmaEssentia Corporation, a biopharma seeking to deliver new biologics in hematology and oncology, has announced that the US Food and Drug Administration (FDA) has accepted the ...
A recent study identified trends in blood counts, but did not find statistically significant associations between achieving hematological remission and clinical outcomes in polycythemia vera (PV) or ...
100% (29/29) of patients experienced platelet count reduction to within normal ranges (150 – 400 x 109/L). 90% (26/29) of patients achieved a platelet count of less than 400 x 109/L without ...
The FDA granted Breakthrough Therapy designation to INCA033989 for the treatment of patients with ET harboring a Type 1 CALR mutation who are resistant or intolerant to at least one cytoreductive ...
Relevance of PIG-A mutation in aplastic anemia and myelodysplastic syndromes. Retrospective analysis of prognostic factors associated with response and overall survival in patients with RAEB-t MDS ...
(MENAFN- GetNews) The Key Essential Thrombocythemia Companies in the market include - Jubilant Therapeutics Inc, Kartos Therapeutics, Inc, Imago BioSciences,Inc., MorphoSys AG, PharmaEssentia ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback